$762.2 M

DRNA Mkt cap, 14-Dec-2018
Dicerna Pharmaceuticals Net income (Q2, 2018)-35.6 M
Dicerna Pharmaceuticals EBIT (Q2, 2018)-35.8 M
Dicerna Pharmaceuticals Cash, 30-Jun-201842.4 M

Dicerna Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

184.0k295.0k1.2m

Revenue growth, %

60%

R&D expense

29.5m44.0m41.7m37.0m

General and administrative expense

15.6m19.2m18.3m25.9m

Operating expense total

45.1m63.2m60.0m62.9m

EBIT

(45.1m)(63.0m)(59.7m)(60.6m)

EBIT margin, %

(34254%)(20254%)(5126%)

Interest expense

199.0k

Interest income

63.0k188.0k235.0k539.0k

Net Income

(47.9m)(62.8m)(59.5m)(60.0m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

184.0k184.0k184.0k162.0k133.0k252.0k474.0k

R&D expense

5.3m6.8m7.5m8.7m11.9m12.1m11.3m11.0m10.1m8.9m9.3m9.0m9.9m10.3m

General and administrative expense

2.8m4.4m3.7m5.4m4.5m4.9m4.5m4.7m4.3m5.5m6.3m6.7m7.5m4.8m

Operating expense total

8.1m11.2m11.2m14.1m16.4m17.0m15.7m15.7m14.4m14.4m15.6m15.7m17.4m37.3m

EBIT

(8.1m)(11.2m)(11.2m)(14.1m)(16.2m)(17.0m)(15.7m)(15.7m)(14.2m)(14.2m)(15.4m)(15.2m)(15.9m)(35.8m)

EBIT margin, %

(8810%)(9239%)(8526%)(8788%)(10706%)(6098%)(3209%)

Interest expense

157.0k42.0k157.0k42.0k176.0k

Interest income

4.0k8.0k21.0k53.0k34.0k55.0k55.0k66.0k61.0k38.0k143.0k179.0k288.0k330.0k

Net Income

(10.8m)(11.4m)(11.2m)(14.1m)(16.2m)(16.9m)(15.7m)(15.6m)(14.2m)(14.2m)(15.2m)(15.0m)(15.6m)(35.6m)

Dicerna Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.1m56.1m20.9m68.8m

Accounts Receivable

254.7m805.4k

Inventories

1.2m1.5m2.0m

Current Assets

97.3m96.1m47.8m118.6m

PP&E

2.2m2.7m2.2m1.5m

Total Assets

103.6m100.0m51.3m120.9m

Accounts Payable

1.2m2.6m4.3m4.9m

Short-term debt

4.6m

Current Liabilities

5.2m9.0m10.0m16.6m

Non-Current Liabilities

106.0k106.0k

Total Liabilities

5.3m9.1m10.0m19.6m

Additional Paid-in Capital

231.7m287.3m297.0m417.0m

Retained Earnings

(133.4m)(196.2m)(255.8m)(315.8m)

Total Equity

91.0m41.2m101.2m

Financial Leverage

1.1 x1.2 x1.2 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

133.8m77.7m31.8m22.6m25.9m52.9m27.6m29.2m32.5m22.9m38.8m31.0m43.0m42.4m

Current Assets

134.7m101.3m93.7m89.1m96.7m95.7m81.8m70.7m59.4m36.2m91.7m79.8m101.8m87.6m

PP&E

911.0k1.5m1.9m2.3m2.6m2.7m2.5m2.5m2.4m2.0m1.8m1.7m1.5m

Total Assets

135.9m124.2m116.0m92.7m127.7m113.6m85.5m74.3m62.9m39.4m94.7m82.7m104.1m89.7m

Accounts Payable

715.0k1.1m1.2m1.8m1.6m1.4m2.4m3.2m3.7m4.1m4.1m5.4m2.0m3.8m

Short-term debt

3.8m

Current Liabilities

6.5m4.0m5.1m6.0m9.0m9.4m7.4m9.4m9.8m10.3m9.6m10.5m14.6m16.2m

Non-Current Liabilities

106.0k106.0k106.0k106.0k8.9m

Total Debt

3.8m

Total Liabilities

6.5m4.0m5.2m6.0m9.0m9.4m7.4m9.4m9.8m10.3m9.6m10.5m16.2m25.1m

Additional Paid-in Capital

225.6m228.0m229.6m234.2m282.3m284.9m290.1m292.5m294.9m299.0m298.4m296.4m419.4m431.7m

Retained Earnings

(96.3m)(107.8m)(118.8m)(147.5m)(163.7m)(180.6m)(211.9m)(227.6m)(241.7m)(270.0m)(285.2m)(300.2m)(331.5m)(367.2m)

Total Equity

86.7m118.7m104.3m78.2m65.0m53.1m29.1m13.3m87.9m64.6m

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.4 x7.1 x1.2 x1.4 x

Dicerna Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(47.9m)(62.8m)(59.5m)(60.0m)

Depreciation and Amortization

848.0k727.0k840.0k778.0k

Accounts Receivable

(15.1m)

Inventories

(44.3m)

Accounts Payable

(97.0k)1.4m1.6m626.0k

Cash From Operating Activities

(20.5m)30.0m(48.7m)(45.3m)

Purchases of PP&E

(2.0m)(1.1m)(449.0k)(133.0k)

Cash From Investing Activities

(75.8m)33.0m13.0m(19.5m)

Long-term Borrowings

(5.0m)

Cash From Financing Activities

90.0m45.8m534.0k112.7m

Interest Paid

194.0k194.0k194.0k

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(10.8m)(22.2m)(33.3m)(14.1m)(16.2m)(47.2m)(15.7m)(15.6m)(45.5m)(14.2m)(44.5m)(15.6m)(51.2m)

Depreciation and Amortization

122.0k213.0k419.0k164.0k529.0k207.0k627.0k571.0k195.0k393.0k

Accounts Payable

(621.0k)(272.0k)(119.0k)525.0k1.6m133.0k(227.0k)3.2m983.0k4.1m1.1m(2.9m)(1.2m)

Cash From Operating Activities

(6.4m)(14.3m)(22.4m)(10.6m)(35.5m)(14.3m)(37.2m)(39.4m)(16.5m)(32.3m)

Purchases of PP&E

(156.0k)(808.0k)(1.0m)(434.0k)(995.0k)(127.0k)(375.0k)(133.0k)(134.0k)(173.0k)

Cash From Investing Activities

(156.0k)(44.5m)(82.2m)7.1m16.6m(14.6m)13.1m(20.0m)(9.9m)5.0m

Cash From Financing Activities

93.8m89.9m89.9m149.0k45.8m466.0k534.0k69.5m632.0k873.0k

Dicerna Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.4 x
Report incorrect company information

Dicerna Pharmaceuticals Employee Rating

2.37 votes
Culture & Values
2.9
Work/Life Balance
2.0
Senior Management
2.5
Salary & Benefits
4.0
Career Opportunities
2.3
Source